Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3
MedComm · 2025-09 · 6 (9)
DOI: 10.1002/mco2.70367 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 03.09.2025. Verfasst von Qi Lv und 14 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Functional Substance of Chinese Medicine School of Pharmacy Nanjing University of Chinese Medicine Nanjing China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The activation of nucleotide oligomerization domain‐like receptor (NLR) family, pyrin domain‐containing protein 3 (NLRP3) inflammasome is implicated in the pathogenesis of various inflammatory diseases. The natural product oridonin possesses a novel mechanism for NLRP3 inhibition and a unique binding mode with NLRP3, but its poor anti‐inflammatory activity limits further application. After virtual screening of diverse natural product libraries, dehydrocostus lactone (DCL) was considered as a potential NLRP3 inhibitor. DCL effectively inhibited caspase‐1 cleavage and release of IL‐1β in mouse and human macrophages at an extremely low concentration of 10 nM, comparable to MCC950. Mechanistically, our study assigned DCL a novel role in disrupting NLRP3 inflammasome assembly and ASC oligomerization. Excluding the influence on potassium/chloride ion efflux, calcium ion influx, and production of mitochondrial ROS, DCL formed a covalent bond with cysteine 280 in NACHT domain of NLRP3, thereby inhibiting the interaction between NLRP3 and NEK7. Furthermore, DCL exhibited protective effects in mouse models of NLRP3 inflammasome‐mediated diseases, including dextran sulfate sodium‐induced colitis, 2,4,6‐trinitrobenzenesulfonic acid‐induced Crohn's disease, LPS‐induced septic shock, and monosodium urate‐induced peritonitis. Our findings identify NLRP3 as the direct target of DCL, positioning DCL as a promising lead compound for treatment of NLRP3 inflammasome‐related diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Functional Substance of Chinese Medicine School of Pharmacy Nanjing University of Chinese Medicine Nanjing China.
- State Key Laboratory of Quality Research in Chinese Medicines Faculty of Chinese Medicine Macau University of Science and Technology Macau China.
- College of Pharmaceutical Science Dali University Dali China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lv, Q., Zhang, Y., Wang, J., Lin, W., Xie, Y., Yang, H., Yin, X., Zhu, Z., Cui, Y., Hu, Y., Zeng, L., Zhang, Y., Chen, X., Liu, J., & Hu, L. (2025). Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3. MedComm, 6(9). https://doi.org/10.1002/mco2.70367
Vancouver
Lv Q, Zhang Y, Wang J, Lin W, Xie Y, Yang H, et al. Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3. MedComm. 2025;6(9). doi:10.1002/mco2.70367
BibTeX
@article{Lv2025,
author = {Lv, Qi and Zhang, Yishu and Wang, Juan and Lin, Weijiang and Xie, Ying and Yang, Hongqiong and Yin, Xunkai and Zhu, Zhenzhen and Cui, Yifan and Hu, Yang and Zeng, Li and Zhang, Yinan and Chen, Xubing and Liu, Jian and Hu, Lihong},
title = {Dehydrocostus Lactone Effectively Alleviates Inflammatory Diseases by Covalently and Irreversibly Targeting NLRP3},
journal = {MedComm},
year = {2025},
volume = {6},
number = {9},
doi = {10.1002/mco2.70367}
}
EUVIMED